Cardiovascular and Pulmonary Branch, National Institutes of Health
Suowen Xu is currently a visiting fellow of National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, USA. The goal of Dr. Xus research is to identify the molecular mechanisms of cardiac hypertrophy and atherosclerosis, and to explore effective therapeutics from Traditional Chinese Medicine, such as Danshen. Dr. Xu now is working on biochemistry of mono-ADP-ribosylation and poly-ADP-ribosylation, a reversible post-translational modification of proteins. Dr. Xu has received numerous honors, including the United States “Committee of 100 (C-100)” Leadership Scholarship, “New Investigator Award” of Ministry of Education of China, “Bayer China Development Fund” Scholarship, and International Health Exchange and Cooperation Center (China) and Daiichi-Sankyo (Japan) Fellowship. He serves as a trainee member of American Heart Association (AHA)-ATVB council. He received his B.Sc. in Traditional Chinese Medicine from Anhui University of Traditional Chinese Medicine, and Ph.D. in cardiovascular pharmacology from Sun Yat-sen University, China.
Atherosclerosis, Hypertension and ADP-ribosylation, Molecular Pathogenesis of Atherosclerosis and Cardiac hypertrophy.